Invesco Ltd. Cara Therapeutics, Inc. Transaction History

Invesco Ltd.

$453 Billion
Q1 2024

A detailed history of Invesco Ltd. transactions in Cara Therapeutics, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 16,942 shares of CARA stock, worth $5,590. This represents 0.0% of its overall portfolio holdings.

Number of Shares

16,942

Previous 16,942 -0.0%

Holding current value

$5,590

Previous $12,000 25.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	SELL	$0.6 - $1.65 $5,676 - $15,609	-9,460 Reduced 35.83%	16,942 $12,000
Q3 2023 Nov 13, 2023	BUY	$1.67 - $3.33 $4,086 - $8,148	2,447 Added 10.21%	26,402 $44,000
Q2 2023 Aug 11, 2023	SELL	$2.83 - $4.94 $471,690 - $823,374	-166,675 Reduced 87.43%	23,955 $67,000
Q1 2023 May 12, 2023	SELL	$4.89 - $12.27 $23,579 - $59,165	-4,822 Reduced 2.47%	190,630 $935,000
Q4 2022 Feb 13, 2023	SELL	$8.88 - $12.77 $688,386 - $989,943	-77,521 Reduced 28.4%	195,452 $2.1 Million

Q3 2022 Nov 14, 2022	BUY	$8.24 - $12.56 $116,167 - $177,070	14,098 Added 5.45%	272,973 $2.56 Million
Q2 2022 Aug 15, 2022	SELL	$7.45 - $13.84 $132,461 - $246,075	-17,780 Reduced 6.43%	258,875 $2.36 Million
Q1 2022 May 16, 2022	SELL	$9.94 - $12.65 $169,387 - $215,568	-17,041 Reduced 5.8%	276,655 $3.36 Million
Q4 2021 Feb 14, 2022	BUY	$11.99 - $18.14 $955,626 - $1.45 Million	79,702 Added 37.24%	293,696 $3.58 Million
Q3 2021 Nov 15, 2021	SELL	$11.55 - $16.06 $205,301 - $285,466	-17,775 Reduced 7.67%	213,994 $3.31 Million
Q2 2021 Aug 17, 2021	BUY	$12.38 - $29.19 $2.73 Million - $6.43 Million	220,449 Added 1947.43%	231,769 $3.31 Million
Q1 2021 May 17, 2021	BUY	$15.07 - $21.71 $170,592 - $245,757	11,320 New	11,320 $246,000

Others Institutions Holding CARA

# of Institutions

102

Shares Held

21.5M

Call Options Held

50K

Put Options Held

View Full List

About Cara Therapeutics, Inc.

Ticker CARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,725,900
Market Cap $17.7M
Description
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...

More about CARA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account